TipRanks
Go Ultimate55% OFF

Nuvectis Pharma (NVCT) Drug Pipeline

Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Nxp900, OsimertinibEgfr Mutation Positive Non-Small Cell Lung Cancer, Egfr Mutated Non-Small Cell Lung Cancer PatientsPhase IRecruitingStudy of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung CancerDec 18, 2025―
Nxp900Advanced Solid Tumor, Renal Cancer, Nsclc (Non-Small Cell Lung Cancer), Mesothelioma, Non-Small Cell Squamous Lung Cancer, Non-Small Cell Lung AdenocarcinomaPhase IRecruitingA Phase 1 Clinical Study of NXP900 in Subjects With Advanced CancersMay 15, 2023
Nxp800Ovarian Cancer, Advanced Solid Tumor, Ovarian Clear Cell Carcinoma, Ovarian Clear Cell Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Endometrioid Tumor, Arid1a Gene MutationPhase IActive Not RecruitingA Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian CancerJan 13, 2022―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Nuvectis Pharma, Inc. (NVCT) have in its pipeline
Nuvectis Pharma NVCT is currently developing the following drugs: Nxp900, Osimertinib, Nxp900, Nxp800. These drug candidates are in various stages of clinical development as the company works toward FDA approval.